• Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers. (Snyder et al., Alzheimer's & Dementia, 2016; Nov;12(11):1177-1185)

• Accelerating drug discovery for Alzheimer's disease: Best practices for preclinical animal studies. (Shineman et al., Alzheimer's Research & Therapy, 2011;3(5):28)

• Preclinical models of Alzheimer's disease: Relevance and translational validity. (Mullane et al., Current Protocols in Pharmacology, 2019; 84, e57:1-28)

• Practical considerations for choosing a mouse model of Alzheimer's disease. (Jankowsky et al., Molecular Neurodegeneration, 2018; Dec 22;12(1):89)

• Harnessing genetic complexity to enhance translatability of Alzheimer's disease mouse models: A path toward precision medicine. (Neuner et al., Neuron, 2019 Feb 6;101(3):399-411)

• Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. (Kilkenny et al., Osteoarthritis Cartilage, 2012;20(4):256-60)

• The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. (Percie du Sert et al., PLOS Biology, 2020; 18(7):e3000410)

• The Experimental Design Assistant. (Percie du Sert et al., Nature Methods, 2017; 14:1024–1025)

• The need for randomization in animal trials: an overview of systematic reviews. (Hirst, J.A., et al., PLoS One, 2014; 9(6): p. e98856)

• Framework for advancing rigorous research. (Koroshetz et al., eLife, 2020; 9: e55915)

• Two decades testing interventions in transgenic mouse models of Alzheimer's disease: designing and interpreting studies for clinical trial success. (Egan et al., Clinical Investigation London, 2014;4(8):693-704)

• Did a change in Nature journals’ editorial policy for life sciences research improve reporting? (The NPQIP Collaborative Group, BMJ Open Science, 2019; 3(1): p. e000035)

• The MDAR (Materials Design Analysis Reporting) Framework for transparent reporting in the life sciences. (Mcleod et al., PNAS, 2021; Vol. 118 No. 17 e2103238118)

• Conserved cell types with divergent features in human versus mouse cortex. (Hodge et al., Nature, 2019; 573(7772):61-68)

• Sex as a biological variable: A 5-year call to action. (Arnegard et al., J Womens Health; 2020 Jun;29(6):858-864)

• Are hormones a "female problem" for animal research? (Shansky, Science, 2019; 364(6443): 825-826)

• Policy: NIH plans to enhance reproducibility. (Collins et al., Nature, 2014;505(7485):612-3)

• Policy: NIH to balance sex in cell and animal studies. (Clayton & Collins, Nature, 2014; 509, pages: 282–283)

• Applying the new SABV (sex as a biological variable) policy to research and clinical care. (Clayton, Physiology & Behavior, 2018; 187:2-5)

• Studying both sexes: A guiding principle for biomedicine. (Clayton, FASEB J. 2016; 30, 519-524) 

• Reporting and misreporting of sex differences in the biological sciences. (Garcia-Sifuentes et al., eLife, 2021;0:e70817)

• Sex difference analyses under scrutiny. (Vorland, eLife, 2021;10:e74135)

• Analysis of sex and gender reporting policies in preeminent biomedical journals. (Bibb et al., JAMA Network Open, 2022;5(8):e2230277)

• A framework for sex, gender, and diversity analysis in research. (Hunt et al., Science, 2022; Vol 377 Issue 6614)

• Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. (Pound et al., Journal of Translational Medicine, 2018; Nov 7;16(1):304)

• Preclinical research: Make mouse studies work. (Perrin, Nature, 2014;507(7493):423-5)

• A call for transparent reporting to optimize the predictive value of preclinical research. (Landis et al., Nature, 2012;490(7419):187-91)

• Promoting an open research culture. (Nosek et al., Science, 2015; 348(6242):1422-5)

• The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: An update. (Bales, Expert Opinion on Drug Discovery, 2012;7(4):281-97)

• Can animal models of disease reliably inform human studies? (van der Worp et al., PLoS Medicine, 2010;7(3):e1000245)

• Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. (Sena et al., PLoS Biology, 2010;8(3):e1000344)

• 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? (Zahs et al., Trends in Neurosciences, 2010;33(8):381-9)

• The rat as an animal model of Alzheimer's disease. (Benedikz et al., Journal of Cellular and Molecular Medicine, 2009;13(6):1034-42)

• Removing obstacles in neuroscience drug discovery: The future path for animal models. (Markou et al., Neuropsychopharmacology, 2009;34(1):74-89)

• Design, power, and interpretation of studies in the standard murine model of ALS. (Scott et al., Amyotrophic Lateral Sclerosis, 2008;9(1):4-15)

• Accelerating biomedical discoveries through rigor and transparency. (Hewitt et al., ILAR Journal, 2017, Vol. 58, No. 1, 115–128)

• The costs of reproducibility. (Poldrak, Neuron, 2019; Jan 2;101(1):11-14)

• Journals unite for reproducibility. (Editorial, Nature, 2014; 515:7)

• Fixing problems with cell lines. (Lorsch et al., Science 2014; Vol 346, Issue 6216; pp. 1452-1453)

• Rigor or mortis: Best practices for preclinical research in neuroscience. (Steward et al., Neuron, 2014; 84(3):572-81)

• Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. Washington DC: 2014 by the National Academy of Sciences; 2014.

• Improving the Utility and Translation of Animal Models for Nervous System Disorders: Workshop Summary. Washington DC: National Academy of Sciences.; 2013.

• Scientists routinely cure brain disorders in mice but not us. A new study helps explain why. (Begley, STAT+ 2019)

• Do the 3Rs need to evolve for modern translational research with mice? (Keater, Ampersand/The Primer Blog, 2022)

• Additional literature on rigor and reproducibility in preclinical research